www.fdanews.com/articles/199088-galera-therapeutics-doses-first-patient-in-phase-2-trial-of-avasopasem-manganese-for-covid-19
Galera Therapeutics Doses First Patient in Phase 2 Trial of Avasopasem Manganese for COVID-19
September 17, 2020
Galera Therapeutics has dosed the first patient in a phase 2 clinical trial of avasopasem manganese (GC4419) for the treatment of critically ill COVID-19 patients.
The trial will evaluate the safety and efficacy of the drug compared to a placebo for improving 28-day mortality in up to 50 hospitalized adults, who will either receive a 90-mg dose of the treatment or a placebo by infusion twice daily for seven days.
Avasopasem manganese is currently under development for radiation-induced severe oral mucositis, a common side effect of chemotherapy.